Restoring mucosal barrier function and modifying macrophage phenotype with an extracellular matrix hydrogel: potential therapy for ulcerative colitis by Keane, Timothy J. et al.
Keane, Timothy J. and Dziki, Jenna and Sobieski, Eric 
and Smoulder, Adam and Castleton, Arthur A and 
Turner, Neill J. and White, Lisa J. and Badylak, Stephen 
F. (2017) Restoring mucosal barrier function and 
modifying macrophage phenotype with an extracellular 
matrix hydrogel: potential therapy for ulcerative colitis. 
Journal of Crohn's and Colitis, 11 (3). 360 -368. ISSN 
1873-9946 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/46418/1/White_ECMH%20for%20Treating%20UC_eprint.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Title: Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an 
Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis 
 
Authors: Timothy J. Keane1,2, Jenna Dziki1,2, Eric Sobieski1,2, Adam Smoulder1,2, Arthur 
Castleton1, Neill Turner1,3, Lisa J. White1,4, Stephen F. Badylak1,2,3,# 
 
Affiliations:  1 McGowan Institute for Regenerative Medicine, Pittsburgh, PA 15219, USA 
2 Dept. of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15213, USA 
3 Dept. of Surgery, University of Pittsburgh, Pittsburgh, PA 15219, USA 
4 School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK 
Short title: ECM Hydrogel for UC Therapy 
 
# Corresponding Author:  Stephen F. Badylak, DVM, Ph.D, MD 
Professor, Department of Surgery and Bioengineering, University of Pittsburgh 
Deputy Director, McGowan Institute for Regenerative Medicine 
450 Technology Drive, Suite 300, Pittsburgh, PA, 15219, USA.  
Tel: 412-624-5253  
Email: badylaks@upmc.edu 
 
Funding: This material is based upon work supported by the NSF Graduate Research Fellowship 
under Grant No. DGE-1247842 (to T.J.K. and J.D.) and by Asana Medical, Inc. The sponsors had 
no role in data collection or analysis. 
 
Author Contributions: TJK and SFB developed study concept and design. TJK, JD, ES, AS, 
AC, NT, and LJW contributed to data acquisition. TJK, JD, and SFB analyzed and interpreted 
data. All authors critically reviewed and approved final version of the manuscript. 
Conflict of interest: The authors have no financial or competing obligations to declare. 
Abstract  
Background & Aims: Despite advances in therapeutic options, more than half of all patients 
with ulcerative colitis (UC) do not achieve long-term remission, many require colectomy, and the 
disease still has a marked negative impact on quality of life. Extracellular matrix (ECM) 
bioscaffolds facilitate the functional repair of many soft tissues by mechanisms that include 
mitigation of pro-inflammatory macrophage phenotype and mobilization of endogenous 
stem/progenitor cells. The aim of the present study was to determine if an ECM hydrogel 
therapy could influence outcomes in an inducible rodent model of UC. 
Methods: The dextran sodium sulfate (DSS)-colitis model was used in male Sprague Dawley 
rats. Animals were treated via enema with an ECM hydrogel and the severity of colitis was 
determined by clinical and histologic criteria. Lamina propria cells were isolated and the 
production of inflammatory mediators was quantified. Mucosal permeability was assessed in-
vivo by administering TRITC-dextran and in-vitro using transepithelial electrical resistance 
(TEER). 
Results: ECM hydrogel therapy accelerated healing and improved outcome. The hydrogel was 
adhesive to colonic tissue, which allowed for targeted delivery of the therapy, and resulted in a 
reduction in clinical and histologic signs of disease. ECM hydrogel facilitated functional 
improvement of colonic epithelial barrier function and the resolution of the pro-inflammatory 
state of tissue macrophages. 
Conclusions: The present study shows that a nonsurgical and nonpharmacologic ECM-based 
therapy can abate DSS-colitis not by immunosuppression but by promoting phenotypic change 
in local macrophage phenotype and rapid replacement of the colonic mucosal barrier. 
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1. INTRODUCTION 
Ulcerative colitis (UC) is one of the most common forms of inflammatory bowel disease, and 
represents a significant global health problem[1]. Since the 1930s, the fundamental approach to 
treatment has been pharmacologic (e.g., 5-amino salicylic acid, immunosuppressive therapy) 
and/or surgical intervention (e.g., colectomy). Nearly a century later, the basic tenets of patient 
care remain unchanged despite inadequate and less than acceptable results. Each year more 
than 50% of UC patients suffer from active flares and associated systemic effects. Overall, 
greater than 20 percent of patients diagnosed with UC will eventually require radical tissue 
resection (i.e. colectomy)—an alarming incidence that has remained unchanged over the last 50 
years[2]. 
UC is a chronic relapsing disease consisting of acute flares followed by periods of remission 
and healing[3]. Active disease is characterized by chronic inflammation of the colon and defects 
in intestinal epithelial cell (IEC) barrier function[4]. Based upon observations that bioscaffolds 
composed of extracellular matrix (ECM) were shown to mitigate inflammation and support 
functional reconstruction of tissues including the gastrointestinal tract [5, 6, 7, 8], we 
hypothesized that a similar approach to UC therapy will (1) abate inflammatory flares not by 
immune suppression but rather by promoting alternative activation of the local immune cell 
population, and (2) induce rapid restoration of the colonic mucosal barrier function not by simply 
providing a physical barrier between colonic submucosa and luminal contents but rather by 
promoting  proliferation and replacement of the colonic  mucosal epithelium. This two-pronged 
approach was tested by local delivery (enema) of an ECM hydrogel in a rodent model of UC.  
The common feature associated with the successful clinical application of ECM bioscaffolds 
has been modulation of the innate immune response via embedded signaling molecules. Intact 
and solubilized/hydrogel forms of ECM have been shown to facilitate a rapid and dramatic 
transition away from an M1-like, pro-inflammatory macrophage phenotype toward an M2-like, 
pro-healing/regulatory macrophage phenotype [9, 10]. Simultaneously, naturally occurring 
cryptic peptide motifs released or exposed during in-vivo degradation of the ECM material, 
combined with the secreted products of ECM-exposed alternatively activated macrophages, 
promote stem/progenitor cell chemotaxis, proliferation, and differentiation [11, 12]. The objective 
of the present study was to determine if the above-mentioned ECM-induced biologic effects 
could influence outcomes in an inducible rodent model of UC.  
 
2. MATERIALS AND METHODS 
2.1.  Experimental design 
Ulcerative colitis was induced in male Sprague Dawley rats and treated with a daily enema 
of ECMH or vehicle (pepsin buffer) only for 7 days to determine the effect of an extracellular 
matrix hydrogel (ECMH) on colonic inflammation and barrier function. Animals were sacrificed at 
7 days and 14 days post-DSS to evaluate the temporal response (n = 14 per time point per 
treatment) as shown in Supplemental Figure 1. Healthy control rats, which did not receive DSS, 
were included for comparison at both 7 and 14 days (n = 6 per time point). The study endpoints 
included clinical response, histologic scores of colon pathology, characterization of the 
inflammatory response, and barrier function. The effect of ECMH on cell phenotype and 
epithelial barrier function was also measured in-vitro with lamina propria mononuclear cells 
(LPMCs) and intestinal epithelial cells, respectively. 
2.2. ECM hydrogel preparation and formulations 
ECM composed of porcine small intestinal submucosa (SIS) was prepared according to a 
standard protocol[13]. In brief, porcine small intestine was harvested immediately following 
euthanasia, rinsed of contents in deionized water, and frozen. The tissue was thawed and the 
tunica mucosa, the tunica serosa, and tunica muscularis externa were mechanically removed, 
leaving behind the tunica submucosa and basilar portions of the tunica mucosa (termed SIS). 
Decellularization of the SIS material was conducted by rinsing in deionized water for 24-72h 
prior to treatment with 0.1% peracetic acid / 4% ethanol and subsequent saline and water 
rinses. SIS-ECM was frozen, lyophilized, and comminuted with a Wiley Mill using a #60-mesh 
screen, and digested at 10 mg/mL dry weight with 1 mg/mL pepsin (Sigma, St. Louis, MO) in 
0.01N HCl while stirring for 20-26 h at 21-23°C. Digest was stored in aliquots at -20°C and pH 
neutralized with 0.1M NaOH prior to use. Hydrogel formation was induced by the neutralization 
step and an accompanying temperature increase to approximately 37°C following administration 
of the enema. All in-vivo studies used an ECM hydrogel (ECMH) concentration of 8 mg/mL and 
all in-vitro studies used an ECMH concentration of 500 μg/mL. The choice of 8 mg/mL ECMH 
concentration was based on a hydrogel concentration that supported robust gel formation within 
10 minutes of placement within the colon, would adhere to the ulcerated colonic wall for greater 
than 12 hours, and did not exhibit time-dependent viscosity as was observed in the 12 mg/mL 
ECMH (Supplemental Figure 2). To examine the effects of ECMH on cell in-vitro, the ECMH 
concentration had to be reduced to prevent gelation within the cell culture and 500 μg/mL was 
used based on previous studies [10, 14]. 
14C-labeled ECMH was prepared as stated above with the intestines of pigs that were 
injected with 14C-tagged proline, as previously described [15]. FITC-labeled ECMH was 
prepared with a protein labeling kit (Thermo PierceNet) per manufacturer’s instructions[11]. 
2.3. ECMH adhesion testing  
 The mucoadhesion strength of ECMH was measured using a modified detachment force 
technique[16]. A uniaxial tensile testing machine (MTS Insight; MTS Systems Corp., Eden 
Prairie, MN) equipped with a 10 N load cell was used for all tensile strength measurements. 
Two colon sections were glued to steel washers (diameter 12.7 mm) with mucosa facing 
outward and one washer was glued to the bottom of a 24-well plate (diameter 15.6 mm). The 
ECMH was prepared by neutralizing with one tenth volume of 0.1M NaOH and one ninth volume 
of 10x PBS then 0.5 mL of ECMH was added onto the bottom tissue and the top tissue was 
added and allowed to penetrate into the gel to a predetermined depth before incubating at 37°C 
for 1 hour. After incubation, the upper washer was slowly withdrawn at a constant speed of 5 
mm/min until a failure occurred between the surfaces. 
2.4. Animals and husbandry 
All procedures and animal studies were approved and conducted in compliance with the 
University of Pittsburgh Radiation Safety Committee and the Institutional Animal Care and Use 
Committee. Male Sprague Dawley rats, 8-12 weeks of age, were obtained from standard vendor 
(Harlan) and were housed and environmentally acclimated for 7-10 days. Animals were housed 
in standard laboratory conditions with a temperature of 21-23 °C and 12 hr dark/light cycles. 
Rats were allowed ad libitum access to food and water throughout the study. 
2.5.  Disease induction and monitoring 
Five percent dextran sulfate sodium (DSS) salt (36,000-50,000 MW; MP Biomedical) was 
prepared daily in deionized water and administered to rats by ad libitum drinking for 7 days and 
the animals were monitored daily. Animal weight and consumption of food and water were 
tracked for each animal. Disease activity (i.e., stool consistency, presence of blood in stool, and 
weight loss) was measured every other day (i.e., days 1, 3, 5, 7, etc.) and scored on a range of 
0 to 4. Stool was scored for consistency (0=normal, 2=loose, 4=diarrhea) and presence of blood 
(0=none, 2=occult, 4=gross bleeding). Stool was tested for the presence of blood using 
ColoScreen ES Lab Pack Fecal Occult Tests. Weight loss compared to baseline was scored as 
follows: 0=none, 1= 1-5%, 2= 5-10%, 3= 10-20%, and 4= >20%. 
2.6. ECMH retention studies with FITC- and 14C-ECMH 
To determine hydrogel retention time, rats were administered FITC-labeled or 14C-labeled 
ECMH via enema following disease induction. Eighteen rats were divided into 2 groups based 
on ECMH formulation (FITC- and 14C-ECMH) and sacrificed at 2 hr, 12 hr, and 24 hr post 
enema (n = 3 per time point per ECMH formulation). Explanted colons from FITC-ECMH treated 
rats were processed to be optically clear such that the luminal contents were visible by 
fluorescent imaging. Immediately following sacrifice all samples were protected from light to 
prevent photo bleaching of the FITC conjugate. Optical clearing of the colons was initiated by 
incubating in Dent’s fixative (1:4 dimethyl sulfoxide (DMSO): acetone) for 2 hours. Colons were 
then permeabilized and bleached in Dent’s bleach (1:4:1 DMSO: acetone: H2O2) for 1 hour. 
Optically cleared colons were then imaged on a Fluorescent gel imager (Chemidoc Touch, 
Biorad). Exposure time was set to a control sample of FITC-ECMH and kept constant for all 
subsequent images. 
For 14C measurements, the entire colon of each rat was individually flash frozen in liquid 
nitrogen and homogenized. The frozen tissue was ground with mortar and pestle and mixed 
until homogenous. Approximately 40 mg of tissue samples was analyzed by accelerated mass 
spectrometry (AMS). Non-treated controls were used to subtract the background 14C levels in 
native tissue. 
2.7. Explanting and scoring of colonic tissue 
Animals were sacrificed at predetermined time points as described previously. Euthanasia 
was achieved by CO2 inhalation and subsequent cervical dislocation in accordance with the 
guidelines of the American Veterinary Medical Association (AVMA). Following euthanasia, the 
colon was resected following a ventral abdominal midline incision. A continuous colon segment 
was collected, spanning from the rectum to the cecum, and photographed. Colon length was 
measured as an indicator of disease activity. The colon was opened longitudinally and assessed 
grossly by investigators blinded to the treatment group for damage according to the metrics 
outlined in Supplemental Table 1.  
The distal region of colon, 9 cm in length, was cut into thirds and opened longitudinally.  
Specimens were then collected for histologic examination, ex-vivo organ culture, and 
myeloperoxidase measurement. The colon specimens were paraffin embedded and tissue 
sections (5 μm) that were obtained from 2 to 8 cm from distal to proximal colon were stained 
with hematoxylin and eosin (H&E) for representative histologic scoring. The distal and proximal 
tissue sections were separated onto 2 slides and histologic scoring was performed according to 
Table 1 by six blinded investigators. 
2.8. TRITC-Dextran permeability assay 
Colonic mucosal permeability was assessed by enteral administration of TRITC-dextran 
(molecular mass 4.4 kDa; Sigma). Rats were administered TRITC-dextran (1mL, 10 mg/mL) 
enema 4 h before sacrifice. Whole blood was obtained at the time of sacrifice in serum 
collection tubes and allowed to clot undisturbed at room temperature for at least 30 minutes. 
The clot was removed by centrifuging at 1,000 x g for 10 minutes at 4°C. TRITC-dextran 
concentration in the serum were determined in triplicate on a SpectraMax plate reader 
(Molecular Devices), with serial dilutions of TRITC-dextran used as a standard curve. 
2.9. Organ cultures 
Full thickness biopsies were obtained following sacrifice from the explanted colon of each 
experimental and control animal at day 7 and day 14 using a 3 mm dermal punch as described 
previously [17]. Tissue specimens were cultured at 37°C with 5% CO2 for 48 h. The supernatants 
were then harvested and stored at -80°C until the amount of TNFα and PGE2 was measured 
using ELISA assays. 
2.10. LPMC isolation and culture 
Lamina propria mononuclear cells (LPMCs) were isolated from rats following colitis induction 
with DSS as described above. The colon was explanted, cleared of mesenteric fat tissue, and 
regions of Peyer’s patches were excised. The colon was then split in half longitudinally, cut into 
pieces, and dissociated into single cell suspensions using a lamina propria dissociation kit 
(Miltenyi) according to manufacturer’s instructions. The suspension was then separated along a 
40/70% Percoll gradient. The cells were suspended in RPMI 1640 containing 10% FBS and 100 
U/mL penicillin and streptomycin, and then placed in 96-well plates at 2×105 cells per well with or 
without the addition of 500 μg/mL ECMH or vehicle (i.e., pepsin buffer).  After 48 hours incubation, 
the supernatant was collected and stored at -80°C until assayed for TNFα and PGE2 with ELISAs. 
2.11. IEC culture 
For in-vitro barrier function assays, IECs (Caco-2, passages 24-28, ATCC) were cultured to 
approximately 80% confluence in MEM containing non-essential amino acids, 1mM sodium 
pyruvate, and 20% FBS. The functional response of IECs to ECMH was evaluated using rapid 
differentiation system (Corning Biocoat HTS Caco-2 Assay) per manufacturer’s instructions. 
Confluent and differentiated cell monolayers were challenged with 100 ng/mL LPS for 2 hours 
and then treated with ECMH for 48 hours.  
2.12. Transepithelial electrical resistance (TEER) measurement 
TEER of Caco-2 monolayers was measured with an Epithelial Voltohmmeter (EVOM2, World 
Precision Instruments). Before seeding Caco-2 cells, electrical resistance of the supporting filter 
and buffer medium was measured and subtracted from the total electrical resistance determined 
with the monolayer to calculate the TEER of the monolayer. Only differentiated monolayers with 
TEER values greater than 300 Ω×cm2 were used in the study. 
2.13. Immunolabeling 
To determine the macrophage response following ECMH treatment, paraffin embedded 
histologic sections were deparaffinized and immunolabeled for a pan-macrophage marker (CD68) 
and indicators of the M1-like (TNF) and M2-like (CD206) macrophage phenotypes. All primary 
antibodies were confirmed to cross-react with rat epitopes. For visualizing the presence of Caco-
2 adhesion proteins, trans-well inserts were fixed in 4% paraformaldehyde and immunolabeled 
for epithelial cadherin (E-cad). Sections were imaged at five random fields per tissue section. 
Quantification of localized staining was achieved using a custom image analysis algorithm 
developed using CellProfiler Image Analysis Software.  
2.14. Statistical analysis 
The sample size used in the present study was determined based on a power analysis using 
pilot study data in combination with previously published relevant studies.  All animals were 
numbered and randomly assigned to a treatment. All investigators responsible for scoring were 
blinded to the experimental groupings. Quantitative outcomes were compared with a one-way or 
two-way analysis of variance (ANOVA) and post-hoc Tukey test to determine differences between 
groups. All statistical analysis was performed using SPSS Statistical Analysis Software (SPSS, 
IBM). Data are reported as mean ± standard deviation unless otherwise stated. 
 
3. RESULTS 
3.1. ECMH is Adhesive to Colon Tissue 
The therapeutic efficacy of ECMH is reliant upon its ability to adhere to the colon wall and 
interface with the resident cells. ECMH has the distinctive property of reverse thermal gelation 
and the hydrogel properties are dependent upon material characteristics (Supplemental Fig 3). 
Results of adhesion testing show that ECMH is mucoadhesive, with a dose-dependent increase 
in adhesion strength when tested on healthy colon (Fig 1A). Importantly, the 8 mg/mL ECMH 
dose used in the present study maintains equivalent adhesion strength in colitic rat colon when 
compared to healthy tissue (Fig 1B).  It is noteworthy that mucosal adherence is not simply a 
property of thermoreversible gels.  For example, Pluronic F-127 (20%; Sigma) did not show 
adhesion strength greater than the negative control (data not shown). When delivered via 
enema to colitic rats, the residence time of the ECMH is greater than 24 hours. Two hours after 
administering the enema, about 50% of the 14C-ECMH remains attached to the colon wall and 
approximately 10% of the initial ECMH enema remained after 24 hours (Fig 1C). These results 
were corroborated by visualization of FITC-ECMH (Fig 1D). Together the results show that 
ECMH material properties at 8 mg/ml allow injection as a liquid and the subsequent rapid 
gelation ensures that the treatment remains localized for at least 24 hr. Based on these data, a 
daily enema treatment was used to measure the therapeutic efficacy of ECMH.  
 
3.2.  ECMH Treatment Mitigates Disease State 
The DSS experimental model is a well-accepted UC-like self-limiting colitis phenotype with 
epithelial barrier defects[18]. Clinical signs of colitis (e.g., weight loss, stool blood, and stool 
consistency) were present following 3 days of exposure to 5% DSS in drinking water and reach 
their peak following 6 days (Supplemental Fig 4). ECMH treatment diminished clinical symptoms 
of UC in this rodent model. ECMH treated animals did not lose as much weight (at days 1 and 
3) and had less blood in stool (at days 3 and 5) compared to the vehicle control. The shortening 
of the colon that was present at day 0 (Supp. Fig 3D) was no longer evident by days 7 and 14 
across all groups (Fig 2D). ECMH treatment resulted in a reduction in the gross score compared 
to the vehicle at day 7 (Fig 2E). Histomorphologic analysis also showed that ECMH is 
therapeutic in the present model and resulted in diminished signs of inflammation and a lower 
the degree of ulceration at 7 and 14 days in both distal and proximal tissue sections (Fig 3 and 
Supplemental Fig 5).  
3.3.  ECMH Restores Epithelial Barrier Function 
A defect in gut barrier function and increased permeability can lead to inflammatory bowel 
disease even in the presence of an intact immune system [19]. Results of the TRITC-Dextran 
permeability assay showed that the barrier function of ECMH-treated animals is similar to 
healthy animals at 7 days while the colonic epithelial barrier in the vehicle-treated control group 
remain impaired compared to the healthy control (Fig 4A). Differentiated and LPS-damaged 
monolayers of IECs respond to ECMH treatment in-vitro with functional recovery as shown by 
TEER readings (Fig 4B). The increased barrier function was associated with an increased 
presence of E-cadherin, one of the most important cell-cell adhesion proteins in the gut. ECMH 
treatment leads to approximately 50% increase in E-cadherin positive cells compared with 
negative controls (Fig 4C-D).  
 
3.4. ECMH Mitigates the Inflammatory Response 
Recognized inflammatory mediators of IBD (i.e., TNFα and PGE2) were measured in the 
present study. LPMCs isolated from colitic rats were plated and exposed to ECMH. The ECMH 
treatment resulted in a substantial reduction in the production of TNFα (Fig 5A) by the LPMCs 
but had no effect on PGE2 production (Fig 5B). Organ cultures of biopsies collected from rats 
following ECMH or vehicle control treatment showed secreted PGE2 was similar to healthy 
controls in the ECMH treated animals while the vehicle controls had significantly elevated levels 
of mucosal PGE2 (Fig 5C). Secreted levels of TNFα were below detection in the organ cultures 
regardless of experimental condition at the time points studied.  
The effect of ECMH on macrophage phenotype in DSS-colitis was evaluated by quantifying 
the number of CD68+ macrophages in the colon that co-express TNFα or CD206. Interestingly, 
the absolute number of individually labeled CD68+, CD206+, and TNFα+ cells was the same 
across all treatment groups (data not shown) but ECMH treatment resulted in a reduction in the 
number of co-labeled CD68+/TNFα+ inflammatory macrophages at day 7 (Fig 5D). The fact that 
ECMH did not affect the amount of global TNFα+ cells but did reduce the number of 
CD68+/TNFα+ cells suggests a direct role for ECMH in modulating the macrophage response by 
reducing the number of inflammatory macrophages present in the colonic tissue. 
 
4. DISCUSSION 
The present study shows that an ECM hydrogel composed of ECM mitigates the 
proinflammatory macrophage phenotype and restores barrier function in a rodent model of UC.  
It is noteworthy that the total number of macrophages was not changed by ECMH treatment, but 
rather the phenotype of this cell population was changed.  In addition, the barrier function was 
not restored by the physical presence of the hydrogel but rather by the restoration of an 
effective mucosal epithelium.  These effects are a distinct departure from the 
immunosuppressive (defensive) and surgical (salvage) methods currently used to treat UC in 
humans. More than half of all patients with UC do not achieve long-term remission and many 
require colectomy. 
UC is a complex immune-mediated disease characterized by diffuse inflammation confined 
to the mucosa and submucosa of the colon and rectum. The inflammatory infiltrate consists of 
neutrophils, lymphocytes, and macrophages that penetrate the epithelium and lead to ulceration 
and crypt abscessation [20]. Macrophages, dependent upon their phenotype, are important 
effector cells of both the initiation/maintenance of inflammatory response  and the 
resolution/regeneration processes. Regulatory M2-like macrophages have been associated with 
mucosal healing outcomes[21, 22] in preclinical models of IBD. Similarly, the restoration of 
functional tissues via ECM bioscaffold mediated events in a variety of regenerative medicine 
applications has been shown to be either associated with, or dependent upon a timely shift in 
macrophage phenotype toward M2 predominance[23, 24, 25]. 
The findings of the present study are consistent with, and analogous to, the known 
mechanisms by which ECM-based approaches facilitate the constructive remodeling of injured 
tissues in other anatomic locations[5, 26, 27, 28, 29, 30]. Specifically, ECM materials derived via 
decellularization of a variety of allogeneic or xenogeneic source tissues have been shown to 
induce a phenotypic transition from the proinflammatory macrophage and lymphocyte 
phenotype toward a regulatory, “anti-inflammatory” and healing phenotype [9, 31, 32, 33], and to 
promote endogenous stem/progenitor cell activation and recruitment [11, 29, 34, 35].  
Furthermore, the findings in the present study are similar to the results in patients with 
esophageal adenocarcinoma who were subjected to complete surgical removal of long segment 
esophageal mucosa and placement of a solid (i.e., not hydrogel) form of an ECM bioscaffold.  
These patients showed a rapid restoration of the esophageal mucosa and esophageal function  
without recalcitrant stricture. 
The combination of promoting a shift in macrophage function from inflammation to wound 
healing and facilitating the restoration of an intact colonic mucosa is a distinct departure from 
current therapeutic strategies for UC, which are focused upon immune suppression (e.g., 
corticosteroids and anti-TNFα compounds) with the associated local and systemic effects.   
Immune suppression is clearly different than maintaining complete functionality of the immune 
system while redirecting its’ biologic objectives. In fact, a robust immune system is necessary 
for a healthy, functional gastrointestinal tract [36, 37, 38, 39].  
The use of immunosuppressive and/or anti-inflammatory compounds has a limited ability to 
facilitate mucosal healing [40, 41], and yet the disrupted mucosal barrier integrity is a key 
component in the pathogenesis of UC. Barrier dysfunction enables the ingress of luminal 
antigens and pathogens, and the continuous  activation of a proinflammatory immune response 
in the lamina propria and the associated chronic inflammation that is the hallmark of UC. 
Restoration of barrier function is therefore an important therapeutic target in UC. In the present 
study, ECMH therapy had a protective downstream effect on the epithelial cells of the colonic 
mucosa. Results show that ECMH facilitated functional improvement of the epithelial barrier 
function and suggests that ECMH acts therapeutically either by limiting epithelial cell damage 
and/or by actively promoting mucosal integrity.  
Recognition that effector cells of the immune system, such as the macrophages and T-
helper cells, not only promote classic inflammatory processes but also orchestrate the temporal 
inhibition of inflammation and initiation of functional tissue remodeling [25, 31, 42, 43, 44, 45] 
provides the opportunity to re-examine immunosuppressive strategies for treatment of diseases 
such as UC. Although the signaling molecules that influence macrophage and lymphocyte 
phenotype transition are not fully understood, there is suggestive evidence that at least some of 
these regulators reside within the ECM [9, 10, 25]. Results of the present study suggest that 
ECMH modulates the innate immune response not by directly promoting an M2-like 
macrophage phenotype but rather by reducing the number of TNF expressing M1-like pro-
inflammatory macrophages, thus shifting the microenvironmental milieu from inflammation to 
repair. It is noteworthy that M2-like macrophages are connected to UC-associated 
carcinogenesis and a sustained M2-like phenotype may not be optimal for UC therapies. 
However, the tumor associated macrophage (TAM) M2-like phenotype differs from the 
regulatory M2-like phenotype associated with tissue restoration [46, 47].  The present study 
showed the  ECMH-mediated macrophage response to be transient and associated with a  
reduction of TNF, a suspected participant in inflammation-mediated colon carcinogenesis[48]. 
[49].   
Limitations of the present study include the use of one animal model and only 2 surface 
markers for macrophage phenotype. The DSS-colitis model was chosen because the model 
features innate immunity and epithelial barrier defects that are central to the present study’s 
hypothesis. The outcomes in the DSS-colitis model can  be effective in predicting clinical 
treatment of IBD [18]. It is well established that when DSS administration is halted, the animals 
will begin to spontaneously recover [50] and therefore differences among groups requires 
examining the temporal response. While only two markers for macrophage phenotype were 
used for immunolabeling, we chose the most representative marker of UC-like inflammation 
(TNF) and for M2-like macrophages (CD206). Macrophages are a heterogeneous and plastic 
cell population and the use of a single marker to delineate phenotype can result in ambiguity. 
TNF, in particular, was chosen for the present study because of its integral role in the 
pathogenesis of UC [51], however it is logical and plausible that the use of other markers could 
provide additional insight into the effects of ECMH treatment upon the resident macrophage 
population in the colitic microenvironment.     
Despite limitations, the present study shows that ECMH restores epithelial barrier function 
and modulates macrophage phenotype away from a pro-inflammatory state. Two physiologic 
processes, the colonic barrier function and pro-inflammatory response, were positively 
influenced by ECMH therapy. Given the mucoadhesive properties of ECMH it would also be 
feasible to use ECMH as a carrier for local delivery of pharmocologics. One benefit of ECMH, in 
addition to the therapeutic efficacy, is that the well-accepted safety profile of ECM products may 
allow for accelerated transition to the clinic. 
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FIGURE LEGENDS 
Figure 1: ECMH is Mucoadhesive. Tensile tests show dose-dependent increase in adhesion 
strength of ECMH to healthy colon (A) and equivalent adhesion in healthy vs. diseased colon (B). 
The resident time of ECMH following enema delivery was tested with 14C (C) and FITC-labeled 
ECMH (D). Scale bar = 1 cm. 
 
Figure 2: ECMH Treatment Reduces Disease Activity. The effect of ECMH treatment on clinical 
symptoms (A-C), colon length (D), and gross score at explant (E) was tracked and compared to 
the vehicle (pepsin) alone.  
 
Figure 3: ECMH Treatment Lowers Histologic Score. Distal and proximal tissue sections stained 
with hematoxylin and eosin were scored by blinded investigators and compared with 
vehicle/pepsin buffer. The extent of inflammation (A, B) and degree of ulceration (C,D) were 
quantified at 7 days. Representative images used for inflammation scoring are shown in panel E. 
 
Figure 4: ECM Restores Barrier Function. TRITC-Dextran permeability assay showed that the 
barrier function of ECMH-treated animals was similar to healthy animals while the colonic 
epithelial barrier in the vehicle-treated control group remained impaired compared to the healthy 
control (A). Differentiated and LPS-damaged monolayers of IECs responded to ECMH treatment 
in-vitro with functional recovery as shown by TEER readings (B). The increased barrier function 
was associated with an increased presence of E-cadherin compared with negative controls (C-
D). Scale bar = 100 μm. 
 
Figure 5: ECMH Mediates Inflammation. Lamina propria cells exposed to ECMH results in 
lowered levels of TNFα (A) but didn’t affect PGE2 production (B). Organ cultures, however 
showed ECMH had a significant impact on PGE2 levels (C). ECMH treatment led to a decrease 
in total number of M1, TNFα expressing macrophages (D). Scale bar = 100 μm. 
 
  
TABLES 
 
 
 
 
  
Table 1. Criteria for histologic scoring of colon specimens 
Feature Score Description 
Inflammation extent 
0 No inflammation 
1 Mild inflammation in mucosa 
2 Moderate-severe inflammation in mucosa 
3 Mild inflammation into the submucosa 
4 Moderate-severe inflammation into the 
submucosa 
Ulceration 
0 0% 
1 1-25% 
2 26-50% 
3 51-75% 
4 76-100% 
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